• Something wrong with this record ?

Improvement of the Diagnosis of Isoattenuating Pancreatic Carcinomas by Defining their Characteristics on Contrast Enhanced Computed Tomography and Endosonography with Fine-Needle Aspiration (EUS-FNA)

R. Psar, O. Urban, M. Cerna, T. Rohan, M. Hill

. 2021 ; 11 (5) : . [pub] 20210426

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21017884

Grant support
IGA_LF_2020_012 Univerzita Palackého v Olomouci

(1) Background. The aim was to define typical features of isoattenuating pancreatic carcinomas on computed tomography (CT) and endosonography and determine the yield of fine-needle aspiration endosonography (EUS-FNA) in their diagnosis. (2) Methods. One hundred and seventy-three patients with pancreatic carcinomas underwent multiphase contrast-enhanced CT followed by EUS-FNA at the time of diagnosis. Secondary signs on CT, size and location on EUS, and the yield of EUS-FNA in isoattenuating and hypoattenuating pancreatic cancer, were evaluated. (3) Results. Isoattenuating pancreatic carcinomas occurred in 12.1% of patients. Secondary signs of isoattenuating pancreatic carcinomas on CT were present in 95.2% cases and included dilatation of the pancreatic duct and/or the common bile duct (85.7%), interruption of the pancreatic duct (76.2%), abnormal pancreatic contour (33.3%), and atrophy of the distal parenchyma (9.5%) Compared to hypoattenuating pancreatic carcinomas, isoattenuating carcinomas were more often localized in the pancreatic head (100% vs. 59.2%; p < 0.001). In ROC (receiver operating characteristic) analysis, the optimal cut-off value for the size of isoattenuating carcinomas on EUS was ≤ 25 mm (AUC = 0.898). The sensitivity of EUS-FNA in confirmation of isoattenuating and hypoattenuating pancreatic cancer were 90.5% and 92.8% (p = 0.886). (4) Conclusions. Isoattenuating pancreatic head carcinoma can be revealed by indirect signs on CT and confirmed with high sensitivity by EUS-FNA.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21017884
003      
CZ-PrNML
005      
20210729104050.0
007      
ta
008      
210726s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/diagnostics11050776 $2 doi
035    __
$a (PubMed)33925859
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Psar, Robert $u Faculty of Medicine and Dentistry, Palacký University Olomouc, 775 15 Olomouc, Czech Republic $u Department of Radiology, Vitkovice Hospital, 703 00 Ostrava-Vitkovice, Czech Republic $u AGEL Research and Training Institute, 796 04 Prostejov, Czech Republic
245    10
$a Improvement of the Diagnosis of Isoattenuating Pancreatic Carcinomas by Defining their Characteristics on Contrast Enhanced Computed Tomography and Endosonography with Fine-Needle Aspiration (EUS-FNA) / $c R. Psar, O. Urban, M. Cerna, T. Rohan, M. Hill
520    9_
$a (1) Background. The aim was to define typical features of isoattenuating pancreatic carcinomas on computed tomography (CT) and endosonography and determine the yield of fine-needle aspiration endosonography (EUS-FNA) in their diagnosis. (2) Methods. One hundred and seventy-three patients with pancreatic carcinomas underwent multiphase contrast-enhanced CT followed by EUS-FNA at the time of diagnosis. Secondary signs on CT, size and location on EUS, and the yield of EUS-FNA in isoattenuating and hypoattenuating pancreatic cancer, were evaluated. (3) Results. Isoattenuating pancreatic carcinomas occurred in 12.1% of patients. Secondary signs of isoattenuating pancreatic carcinomas on CT were present in 95.2% cases and included dilatation of the pancreatic duct and/or the common bile duct (85.7%), interruption of the pancreatic duct (76.2%), abnormal pancreatic contour (33.3%), and atrophy of the distal parenchyma (9.5%) Compared to hypoattenuating pancreatic carcinomas, isoattenuating carcinomas were more often localized in the pancreatic head (100% vs. 59.2%; p < 0.001). In ROC (receiver operating characteristic) analysis, the optimal cut-off value for the size of isoattenuating carcinomas on EUS was ≤ 25 mm (AUC = 0.898). The sensitivity of EUS-FNA in confirmation of isoattenuating and hypoattenuating pancreatic cancer were 90.5% and 92.8% (p = 0.886). (4) Conclusions. Isoattenuating pancreatic head carcinoma can be revealed by indirect signs on CT and confirmed with high sensitivity by EUS-FNA.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Urban, Ondrej $u Department of Internal Medicine II-Gastroenterology and Geriatrics, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, 775 15 Olomouc, Czech Republic
700    1_
$a Cerna, Marie $u Department of Radiology, Faculty of Medicine, University Hospital Olomouc, Dentistry Palacký University Olomouc, 779 00 Olomouc, Czech Republic
700    1_
$a Rohan, Tomas $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, 625 00 Brno, Czech Republic
700    1_
$a Hill, Martin $u Institute of Endocrinology, 116 94 Prague, Czech Republic
773    0_
$w MED00195450 $t Diagnostics (Basel, Switzerland) $x 2075-4418 $g Roč. 11, č. 5 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33925859 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729104049 $b ABA008
999    __
$a ind $b bmc $g 1676456 $s 1138326
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 5 $e 20210426 $i 2075-4418 $m Diagnostics $n Diagnostics $x MED00195450
GRA    __
$a IGA_LF_2020_012 $p Univerzita Palackého v Olomouci
LZP    __
$a Pubmed-20210726

Find record

Citation metrics

Archiving options